Hemispherx Biopharma, Inc. (NYSE:HEB) traded at an unexpectedly low level on 03/27/2017 when the stock experienced a 8.72 gain to a closing price of $0.55. The company saw 0.15 million shares trade hands over the course of the day. Given that its average daily volume over the 30 days has been 0.26 million shares a day, this signifies a pretty significant change over the norm. Hemispherx Biopharma, Inc. (HEB) Analyst Gushes
Analysts are speculating a 1994.55% move, based on the high target price ($11.52) for the shares that is set to reach in the next 12 months. The analysts, on average, are forecasting a $11.52 price target, but the stock is already up 41.23% from its recent lows. However, the stock is trading at -79.14% versus recent highs ($2.6352). Analysts believe that we could see stock price minimum in the $11.52 range (lowest target price), allowing for another 1994.55% jump from its current position. Leading up to this report, we have seen a 10.16% rise in the stock price over the last 30 days and a -20.17% decline over the past 3 months. Overall, the share price is down -20.17% so far this year. Additionally, HEB had a day price range of $0.53 to $0.5847. Hemispherx Biopharma, Inc. Rating Changes
Several analysts are currently covering the company. Midtown Partners, Chardan Capital Markets, Boenning & Scattergood, , , , , , and are among others. The latest initiating coverage report came from Midtown Partners on Apr 02, 2015. The stock has been given a Strong Buy rating. In a separate analyst note, Chardan Capital Markets initiated HEB on Jan 21, 2014. The firm had put out a Buy rating. Back on Dec 10, 2007, a downgrade report came from equity analysts at Boenning & Scattergood who in their research findings assigned Market Perform rating on the stock. The brokerage had Market Outperform rating prior to this move. Hemispherx Biopharma, Inc. (HEB) Price Potential
Heading into the stock price potential, Hemispherx Biopharma, Inc. needs to grow just 1994.55% to cross its median price target of $11.52. In order to determine directional movement, the 50-day and 200-day moving averages for Hemispherx Biopharma, Inc. (NYSE:HEB) are $0.51 and $0.83. Given that liquidity is king in short-term, HEB is a stock with 27.22 million shares outstanding that normally trades 2.05% of its float. The stock price recently experienced a 5-day gain of 0.15% with 0.04 average true range (ATR). HEB has a beta of -0.28 and RSI is 51.11.
